Notice of Intent to Sole Source - EzPlaz
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT942726QE015
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Special Notice indicating its intent to award a sole source, firm-fixed price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for the supply of FDA-approved Freeze Dried Plasma (FDP) products. This procurement is managed by the DHA Contracting Activity (DHACA) on behalf of the Portfolio Acquisition Executive Medical Products (PAE MP) division. The contract will be executed with Vascular Solutions LLC, located at 6420 Sycamore Ct N, Maple Grove, Minnesota, as they are identified as the only responsible source capable of meeting the agency’s critical requirements.
The primary objective of this procurement is to ensure the reliable supply of EZPLAZ™, a freeze dried plasma product approved by the Food and Drug Administration (FDA) on July 29, 2026. EZPLAZ™ is currently the first and only FDA-licensed FDP product available on the market. The product is intended for transfusion in situations where plasma is required and other plasma products are not available, addressing a vital need within the military medical system for rapid and effective blood product support in emergent or austere environments.
The scope of the contract encompasses the ongoing supply of this specialized pharmaceutical preparation, classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505. The place of performance is designated as Maryland, United States.
This notice is not a solicitation for competitive proposals; rather, it serves as a public declaration of the Government’s intent to proceed with a sole source award unless it is demonstrated that another source can meet the stringent requirements. Interested parties who believe they can provide an FDA-approved FDP product are invited to submit a detailed capability statement. Submissions must include comprehensive management, technical, and cost information, and must clearly demonstrate the ability to meet the Government’s needs with an FDA-approved product. Capability statements are limited to five pages (8.5 x 11 inches, minimum 10-point font) and must be submitted electronically in Microsoft Word or Adobe PDF format.
All capability statements must be received by 3:00 PM local time on September 16, 2026. Submissions should be sent via email to both Timothy Kelly ([email protected]) and Shannon Lertora ([email protected]). The Government will review all responses received by the deadline to determine whether a competitive procurement is warranted. If no qualified responses are received, the contract will be awarded to Vascular Solutions LLC without further notice.
This procurement is classified as a Special Notice under the authority of FAR 6.103-1, which allows for sole source awards when only one responsible source is available and no other supplies or services will satisfy agency requirements. There are no set-aside requirements or additional attachments associated with this notice.
Contractors considering this opportunity should note the unique requirement for an FDA-approved freeze dried plasma product and the Government’s intent to proceed with a sole source award unless compelling evidence of alternative sources is provided. The opportunity remains active, and all relevant details can be found on the official SAM.gov listing (Opportunity ID: 5dda764058414494a13827d6b4ad2a6e).